Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (101-110 of 156) with videos related to

Pageof 16
Sort By:
International Journal of Oncology|October 18, 2016
MEK inhibitors against MET-amplified non-small cell lung cancerMasato Chiba, Yosuke Togashi, Shuta Tomida, et al.
Molecular Cancer Therapeutics|May 22, 2016
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCCYu Nakamura, Yosuke Togashi, Hirokazu Nakahara, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2026
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer modelAyako Morita, Kammei Rai, Tadahiro Kuribayashi, et al.
International Immunology|December 24, 2019
The potential application of PD-1 blockade therapy for early-stage biliary tract cancerKumiko Umemoto, Yosuke Togashi, Yasuhito Arai, et al.
Immunity|July 9, 2020
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T CellsShogo Kumagai, Yosuke Togashi, Chika Sakai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2Masato Terashima, Yosuke Togashi, Katsuaki Sato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor ImmunityTokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, et al.
JCI Insight|March 23, 2021
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancerKoji Inamori, Yosuke Togashi, Shota Fukuoka, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, et al.
Pageof 16

Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
International Journal of Oncology|October 18, 2016
MEK inhibitors against MET-amplified non-small cell lung cancerMasato Chiba, Yosuke Togashi, Shuta Tomida, et al.
Molecular Cancer Therapeutics|May 22, 2016
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCCYu Nakamura, Yosuke Togashi, Hirokazu Nakahara, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2026
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer modelAyako Morita, Kammei Rai, Tadahiro Kuribayashi, et al.
International Immunology|December 24, 2019
The potential application of PD-1 blockade therapy for early-stage biliary tract cancerKumiko Umemoto, Yosuke Togashi, Yasuhito Arai, et al.
Immunity|July 9, 2020
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T CellsShogo Kumagai, Yosuke Togashi, Chika Sakai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2016
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2Masato Terashima, Yosuke Togashi, Katsuaki Sato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor ImmunityTokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, et al.
JCI Insight|March 23, 2021
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancerKoji Inamori, Yosuke Togashi, Shota Fukuoka, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2019
PD-1<sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancerTakahiro Kamada, Yosuke Togashi, Christopher Tay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, et al.
Pageof 16